[L-tryptophan therapy of DOPA psychoses].
D000368:Aged; D001264:Athetosis / Q000139:chemically induced; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002819:Chorea / Q000139:chemically induced; D003248:Constipation / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000009:adverse effects* / Q000627:therapeutic use; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy; D011605:Psychoses, Substance-Induced / Q000188:drug therapy*; D012640:Seizures / Q000139:chemically induced; D012893:Sleep Wake Disorders / Q000139:chemically induced; D014364:Tryptophan / Q000008:administration & dosage / Q000627:therapeutic use*; D014717:Vertigo / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D004295:Dihydroxyphenylalanine; D014364:Tryptophan
Die Behandlung der DOPA-Psychosen mit L-Tryptophan.